[{"indications": "Indications\u00a0benign gastric and duodenal ulceration;\r\nsee also Helicobacter pylori infection, section 1.3", "name": "TRIPOTASSIUM DICITRATOBISMUTHATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.3 Antisecretory drugs and mucosal protectants", "1.3.3 Chelates and complexes", "TRIPOTASSIUM DICITRATOBISMUTHATE"], "cautions": "Cautions\u00a0\n(From 1.3.3 Chelates and complexes: British National Formulary)\nThe bismuth content of tripotassium dicitratobismuthate is low but absorption has been reported; encephalopathy (described with older high-dose bismuth preparations) has not been reported.; interactions: Appendix 1 (tripotassium dicitratobismuthate)", "side-effects": "Side-effects\u00a0may darken tongue and blacken faeces; less commonly nausea, vomiting, diarrhoea, constipation,\r\nrash, and pruritus reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2130.htm", "doses": ["2 tablets twice daily or 1 tablet 4 times\r\ndaily; taken for 28 days followed by further 28 days if necessary;\r\nmaintenance not indicated but course may be repeated after interval\r\nof 1 month; child not recommended"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid on theoretical grounds"}]